相关实验视频

Updated: Jan 7, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K

罗马西克利布是一种CDK8/CDK19抑制剂,可以通过组合策略克服venetoclax耐药性

Urszula Pakulska, Marta Obacz, Jerzy Woźnicki

    bioRxiv : the preprint server for biology
    |December 25, 2025
    PubMed
    概括

    与venetoclax结合的Romacliclib在克服急性髓性白血病 (AML) 的抗药性方面表现有前途. 这种组合疗法有效地向耐性白血病细胞,并支持骨髓恢复,为AML患者提供了新的希望.

    更多相关视频

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

    Published on: June 17, 2022

    3.5K
    Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

    Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

    Published on: March 30, 2019

    8.0K

    相关概念视频

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    5.5K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.8K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.7K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.6K
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    9.8K